Telix Pharmaceuticals (TLX) News
What's actually happening: chronological and provenance-stamped. News is context, not a signal.

/PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") will participate in the upcoming UBS Global Biopharma Conference in London (UK)…

Telix Pharmaceuticals NASDAQ: TLX outlined its commercial growth strategy, late-stage radiopharmaceutical pipeline and planned integration of ITM at an investor event in Melbourne, with management emphasizing supply-chai…

Telix Pharmaceuticals maintains a buy rating, driven by robust 3Q26 performance and the strategic ITM acquisition to diversify revenue and strengthen isotope supply. 3Q26 revenue rose 19% YoY to $245 million, with Precis…

MELBOURNE, Australia and INDIANAPOLIS, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) provides a financial update on its commercial and operational performance for the qu…

The joint venture between IBA and Framatome will leverage Telix's capabilities to accelerate the production and availability of Astatine-211 in the US market.…

MELBOURNE, Australia and LOUVAIN-LA-NEUVE, Belgium and PARIS and INDIANAPOLIS, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) and Ekalia, a joint venture between IBA (Ion…

Collaboration will educate physicians and prostate cancer centers on the complementary roles of Telix's PSMA-PET molecular imaging technologies and Profound's MRI-guided TULSA-PRO ® Agreement provides Profound with incre…

MELBOURNE, Australia and INDIANAPOLIS, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that the first patients in the United States (U.S.) have been dosed …

IBA to offer QUANTM® Irradiation System solid-target technology to cyclotron users worldwide, scaling local production of radiometals for theranostics…

The average of price targets set by Wall Street analysts indicates a potential upside of 83.4% in Telix Pharmaceuticals Limited (TLX). While the effectiveness of this highly sought-after metric is questionable, the posit…

Telix Pharmaceuticals Limited (NASDAQ: TLX - Get Free Report) saw unusually-strong trading volume on Monday. Approximately 231,111 shares changed hands during trading, an increase of 4% from the previous session's volume…

Telix Pharmaceuticals Limited (TLX) Discusses Strategic Overview and Oncology Pipeline at Research and Development Day Transcript…

Telix Pharmaceuticals Limited (TLX) M&A Call Transcript…

MELBOURNE, Australia and INDIANAPOLIS and MUNICH, Sept. 21, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces it has signed a strategic agreement to lead a merger wit…

Australia's Telix Pharmaceuticals said on Monday it has agreed to acquire Germany-based ITM Isotope Technologies Munich SE for about $1.65 billion on a cash- and debt-free basis.…

Telix Pharmaceuticals is maintained at a “Buy” rating, supported by FDA approval of PIXCLARA and robust pipeline progress in oncology diagnostics and therapeutics. The company achieved the first FDA-approved FET-PET imag…

Telix Pharmaceuticals Limited (TLX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript…

On Monday, the U.S. Food and Drug Administration (FDA) approved Pixclara (floretyrosine F18), an amino acid positron emission tomography (PET) imaging agent created by Telix Pharmaceuticals Limited (NASDAQ:TLX) to diagno…

MELBOURNE, Australia and INDIANAPOLIS, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that the United States (U.S.) Food and Drug Administration (FDA) ha…

MELBOURNE, Australia and INDIANAPOLIS, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) advises that Dr. Christian Behrenbruch, Managing Director and Group CEO and Kevin R…

MELBOURNE, Australia and INDIANAPOLIS, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announced completion of patient enrollment in the Phase 3 BiPASS™ study of it…

MELBOURNE, Australia and INDIANAPOLIS, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix” or the “Company”) today announces that David Gill has been appointed Chair of the Bo…

Telix Pharmaceuticals has rebounded strongly, reaching profitability and guiding FY2026 revenue to $950–$970 million, driven by precision medicine sales. Key catalysts include imminent FDA decisions for TLX101-Px (brain …
Kept in their own lane. A press release is the company talking, not reporting.
No upcoming events in the feeds.

